医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Elekta CE Marks Leksell Gamma Knife® Icon™, designed to treat a more expansive range of cranial targets

2015年06月09日 PM09:44
このエントリーをはてなブックマークに追加


 

STOCKHOLM, Sweden

Regulatory News:

Elekta has CE marked its Leksell Gamma Knife® Icon™ (http://www.careforthebrain.com/) precision radiosurgery system, making this latest generation Leksell Gamma Knife platform available in the European market. With stereotactic imaging, online Adaptive DoseControl™, ultra-precise dose delivery and the availability of frameless treatments, Icon is capable of treating virtually any target in the brain, regardless of type, location or volume. The company also announced that University Hospital La Timone (Marseilles, France) had installed the first Icon and will use the system to treat the first patients in July.

“Leksell Gamma Knife Icon is a new concept for performing precision radiosurgery for all types of cranial cases with unlimited clinical and workflow flexibility,” says Tomas Puusepp, President and CEO of Elekta. “Clinicians can choose either frame-based or frameless methods to immobilize the patient’s head, as well as the option to perform the treatment in a single session or in multiple sessions. Icon is also based on the only technology available that can perform ultra-precise Microradiosurgery™ for the cases where this is required.”

Puusepp adds that the system’s online Adaptive DoseControl™ and high-definition motion management features ensure the most precise treatments possible, whether frame-based or frameless, as well as an efficient workflow thanks to the complete system and workflow integration.

Professor Jean Régis, MD, a neurosurgeon and program director for University Hospital La Timone’s Gamma Knife program, says that Icon presents physicians with two significant opportunities related to the ability to use frameless immobilization.

“The first will be to enlarge the scope of indications by permitting hypofractionation [multiple treatment sessions] to be performed more readily, and also treatment of lesions in additional anatomical sites. This is by virtue of the capability to perform frameless treatments with much better technical control,” he says. “The second opportunity is the ability to evaluate shifts in the patient’s position and to adapt the dose proactively to account for these movements. This in particular, will push frameless, hypofractionated radiosurgery to a level that doesn’t exist today.”

University Hospital La Timone physicians are long-time users of the predecessor of Icon, Leksell Gamma Knife® Perfexion™, having been the world’s first hospital to treat patients with the system in 2006. In 2010, the hospital used its Perfexion to deliver radiosurgery to the center’s 10,000th patient. University Hospital La Timone’s Gamma Knife program is 23-years-old and has employed four different versions of Leksell Gamma Knife.

For more information on Icon, visit www.careforthebrain.com.

Elekta has submitted Leksell Gamma Knife Icon for US FDA 510(k) clearance.

# # #

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 14:30 CET on June 9, 2015.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Elekta AB (publ) P.O. Box 7593 SE-103 93 Stockholm Sweden www.elekta.com Elekta AB (publ), Reg No. 556170-4015

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150609005973/en/

CONTACT

Kris Walmsley
Corporate Communications Manager
Elekta AB (publ)
Office:
+46 8 587 25471 | Mobile: +46 70 537 9545
Kris.Walmsley@elekta.com
or
For
further information, please contact:
Gert van Santen, Group Vice
President Corporate Communications,
Elekta AB Tel: +31 653 561 242,
e-mail:
gert.vansanten@elekta.com
Time
zone: CET: Central European Time
or
Johan Andersson, Director,
Investor Relations,
Elekta AB Tel: +46 702 100 451,
e-mail: johan.andersson@elekta.com
Time
zone: CET: Central European Time

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent